What is ARA-290?

Overview

ARA-290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the naturally occurring hormone erythropoietin (EPO). Unlike EPO, ARA-290 was specifically engineered to retain its tissue-protective properties while avoiding stimulation of red blood cell production.

Researchers continue to investigate ARA-290 across several areas of regenerative medicine, particularly those involving nerve biology, inflammation, tissue protection, and cellular repair mechanisms.

Its unique mechanism of action has made ARA-290 an important research compound within the fields of neurobiology and regenerative science.

Mechanism of Interest

ARA-290 functions by selectively activating the Innate Repair Receptor (IRR), a receptor complex formed by the erythropoietin receptor (EPOR) and the beta-common receptor (CD131). Unlike native erythropoietin, ARA-290 does not activate the classical receptor responsible for red blood cell production.

Researchers are interested in understanding how activation of the Innate Repair Receptor may influence biological processes involved in cell survival, tissue repair, neuroprotection, and the regulation of inflammatory signalling.

Its selective receptor profile distinguishes ARA-290 from erythropoietin itself and continues to make it an important subject of ongoing scientific investigation.

Areas of Ongoing Research

ARA-290 continues to be studied in several fields of research, including:

• Neuroprotection

• Peripheral nerve biology

• Tissue repair and regeneration

• Inflammation research

• Neuropathic pain research

• Innate Repair Receptor signalling

• Cellular protection following tissue injury

Scientists continue to investigate the various ways ARA-290 may interact with these biological systems.

Why Researchers Are Interested in ARA-290

Researchers are interested in ARA-290 because of its novel mechanism of action and its selective interaction with the Innate Repair Receptor.

Unlike erythropoietin, which stimulates red blood cell production, ARA-290 was specifically designed to investigate tissue-protective signalling independently of haematopoietic activity. This has made it an important research tool for exploring biological mechanisms involved in nerve function, inflammation, tissue repair, and cellular resilience.

Its distinctive pharmacological profile and ongoing clinical investigation continue to make ARA-290 a significant area of scientific research.

Related Compounds

Researchers exploring ARA-290 may also be interested in other compounds commonly studied within similar areas of research, including:

• BPC-157

• TB-500

• KPV

• GHK-CU

• Thymosin Alpha-1

While these compounds differ in their mechanisms of action, they share overlapping areas of scientific interest relating to tissue repair, inflammation, regenerative biology, and cellular protection.

Disclaimer

The information provided within the Sterling Prime Research Hub is intended for educational and informational purposes only.

Products sold by Sterling Prime Peptides are supplied strictly for laboratory research use only and are not intended for human consumption, therapeutic use, diagnosis, prevention, or treatment of disease.

Sterling Prime Peptides makes no claims regarding the safety or effectiveness of any research compound outside of approved scientific settings. Researchers are responsible for ensuring they comply with all applicable laws, regulations, and ethical standards governing their work.